investors

Press Releases

DateTitle and SummaryView
April 30, 2015
LOS ANGELES , April 30, 2015 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT: IMUC) today announced that it plans to report financial results for the first quarter 2015 on Monday, May 11, 2015 . The Company also plans to hold a conference call and webcast on
ImmunoCellular Therapeutics to Report First Quarter 2015 Financial Results on May 11, 2015; Conference Call and Webcast to be Held on May 12, 2015
March 19, 2015
LOS ANGELES and MAASTRICHT, The Netherlands , March 19, 2015 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT: IMUC) today announced the establishment of an agreement with PharmaCell B.V. to provide contract manufacturing services for the European production of
ImmunoCellular Therapeutics Establishes Manufacturing Agreement with PharmaCell B.V. for European Production of ICT-107 for Phase 3 Registration Trial
March 9, 2015
ICT-107 Poised to Begin Phase 3 Registration Trial in Second Half of 2015; Business Update Conference Call to be Held on March 12, 2015
ImmunoCellular Therapeutics Announces Fourth Quarter and Full Year 2014 Financial Results
March 3, 2015
LOS ANGELES , March 3, 2015 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT: IMUC) today announced that Andrew Gengos , Chief Executive Officer of ImmunoCellular , will present a corporate overview and business update at the 27 th Annual ROTH Conference on Tuesday,
ImmunoCellular Therapeutics to Present at ROTH Conference on March 10th
March 2, 2015
LOS ANGELES , March 2, 2015 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT: IMUC) today announced that it plans to report financial results for the year ended December 31, 2014 on March 9, 2015 . The Company also plans to hold a business update conference call and
ImmunoCellular Therapeutics to Report 2014 Financial Results on March 9, 2015; a Business Update Conference Call and Webcast is Scheduled for March 12, 2015
February 18, 2015
LOS ANGELES , Feb. 18, 2015 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT: IMUC) today announced the appointment of Steven J. Swanson , PhD, as Senior Vice President, Research. Dr. Swanson will lead the Company's Stem-to-T-cell research program, which utilizes the
ImmunoCellular Therapeutics Strengthens Executive Management Team with Appointment of Dr. Steven Swanson to Lead Stem-to-T-Cell Program
February 12, 2015
LOS ANGELES , Feb. 12, 2015 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT: IMUC) today announced that it has priced an underwritten public offering of an aggregate of 26,650,000 shares of its common stock at a price to the public of $0.60 per share, and warrants
ImmunoCellular Therapeutics, Ltd. Announces Pricing of a Public Offering of Common Stock and Warrants
January 28, 2015
LOS ANGELES , Jan. 28, 2015 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT: IMUC) today announced that Andrew Gengos , Chief Executive Officer, will present a corporate overview and business update at the 17 th Annual BIO CEO & Investor Conference at 2:00 pm ET on
ImmunoCellular Therapeutics to Present at the BIO CEO & Investor Conference on February 9, 2015
December 17, 2014
LOS ANGELES , Dec. 17, 2014 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT: IMUC) announced that the US Patent and Trademark Office (USPTO) has issued a key patent covering ImmunoCellular's product candidate ICT-107, a dendritic cell-based immunotherapeutic vaccine
ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine
December 1, 2014
LOS ANGELES , Dec. 1, 2014 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") ( NYSE MKT : IMUC) today announced that the European Medicines Agency (EMA) has provided scientific advice supportive of advancing ICT-107 to a registrational phase III program in patients with newly
ImmunoCellular Therapeutics Receives Positive Regulatory Feedback from European Medicines Agency on Advancing ICT-107 to Phase III Program
Copyright 2018 by Immunocellular Therapeutics, Ltd.
All Rights Reserved